A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs Avacincaptad pegol (Primary)
- Indications Stargardt disease
- Focus Therapeutic Use
- Sponsors OphthoTech Corporation
- 01 Dec 2017 Status changed from planning to not yet recruiting.
- 08 Nov 2017 According to an OphthoTech Corporation media release, initial top-line data are expected to be available in 2020.
- 31 Jul 2017 New trial record